Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 May 18;5(1):10.
doi: 10.1186/1471-2431-5-10.

Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia

Heather Hodgson-Viden  1 , Paul E Grundy, Joan L Robinson
Affiliations

Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia

Heather Hodgson-Viden et al. BMC Pediatr. .

Abstract

Background: There are no standard criteria for when to discontinue intravenous antimicrobial therapy (IVAMT) in children with febrile neutropenia (FN), but it is now common to discontinue IVAMT and discharge patients with an absolute neutrophil count (ANC) < or = 500/mm3. The purpose of this study was to evaluate the outcome of a large cohort of children with FN who had IVAMT discontinued with an ANC < or = 500/mm3

Methods: A retrospective chart review was completed of patients in the Northern Alberta Children's Cancer Program with FN and no apparent clinical source of fever from June 1, 1997 to July 1, 2002.

Results: Out of a total of 275 patients, 127 (46%) had at least one episode of FN, with FN occurring in patients with sarcomas more commonly than in those with leukemia/ lymphoma and least in those with other solid tumors. In 59 of 276 episodes of FN (21%) patients had a microbiologically defined infection at admission. Of the 217 remaining episodes, 112 of 199 patients (56%) with known neutrophil counts had IVAMT discontinued before their absolute neutrophil count (ANC) reached 500/mm3 at the discretion of the clinician. Fever recurred in only two of these patients after discharge, and there were no bacterial infections diagnosed after parenteral antibiotics were discontinued.

Conclusion: Even without use of standard criteria for early discharge, clinicians appear to be skilled at selecting children with FN who can safely have IVAMT discontinued with an ANC < or = 500/mm3.

PubMed Disclaimer

References

    1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751. doi: 10.1086/339215. - DOI - PubMed
    1. Woo PC, Wong SS, Lum PN, Hui W, Yuen K. Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients. Lancet. 2001;357:675–679. doi: 10.1016/S0140-6736(00)04131-3. - DOI - PubMed
    1. Heussel CP, Kauczor HU, Heussel GE, Fischer B, Begrich M, Mildenberger P, Thelen M. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem cell transplant recipients: use of high-resolution computer tomography. J Clin Oncol. 1999;17:796–805. - PubMed
    1. Klaassen RJ, Allen U, Doyle JJ. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J Pediatr Hematol Oncol. 2000;22:405–411. doi: 10.1097/00043426-200009000-00004. - DOI - PubMed
    1. Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol. 2002;39:77–85. doi: 10.1002/mpo.10073. - DOI - PubMed

Publication types

MeSH terms

Substances